nifenazone has been researched along with Cardiomyopathies in 1 studies
nifenazone: RN given refers to parent cpd; structure
Cardiomyopathies: A group of diseases in which the dominant feature is the involvement of the CARDIAC MUSCLE itself. Cardiomyopathies are classified according to their predominant pathophysiological features (DILATED CARDIOMYOPATHY; HYPERTROPHIC CARDIOMYOPATHY; RESTRICTIVE CARDIOMYOPATHY) or their etiological/pathological factors (CARDIOMYOPATHY, ALCOHOLIC; ENDOCARDIAL FIBROELASTOSIS).
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (100.00) | 2.80 |
Authors | Studies |
---|---|
Zhang, Y | 1 |
Li, Y | 1 |
Hu, Q | 1 |
Xi, Y | 1 |
Xing, Z | 1 |
Zhang, Z | 1 |
Huang, L | 1 |
Wu, J | 1 |
Liang, K | 1 |
Nguyen, TK | 1 |
Egranov, SD | 1 |
Sun, C | 1 |
Zhao, Z | 1 |
Hawke, DH | 1 |
Li, J | 1 |
Sun, D | 1 |
Kim, JJ | 1 |
Zhang, P | 1 |
Cheng, J | 1 |
Farida, A | 1 |
Hung, MC | 1 |
Han, L | 1 |
Darabi, R | 1 |
Lin, C | 1 |
Yang, L | 1 |
1 other study available for nifenazone and Cardiomyopathies
Article | Year |
---|---|
The lncRNA H19 alleviates muscular dystrophy by stabilizing dystrophin.
Topics: Animals; Antipyrine; Cardiomyopathies; Cell Line; Disease Models, Animal; Dystrophin; Enzyme Inhibit | 2020 |